Treatment potential of tirzepatide or semaglutide in patients with metabolic hepatic steatosis (MASLD) or metabolic steatohepatitis (MASH): A systematic review and meta-analysis.

• Grant number: 24/08745-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: November 01, 2024
• End date: October 31, 2025
• Field of knowledge: Health Sciences - Collective Health - Public Health
• Principal Investigator: Silvia Helena de Carvalho Sales Peres
• Grantee: Ricardo Pinal de Mello
• Host Institution: Faculdade de Odontologia de Bauru (FOB). Universidade de São Paulo (USP). Bauru , SP, Brazil

Abstract

Metabolic hepatic steatosis (MASLD) and its possible progression to metabolic steatohepatitis (MASH) are a topic of public health importance as they have a high prevalence (estimated 30%) and unfavorable clinical outcomes, with mortality mainly related to cardiovascular events. GLP-1 receptor agonists have demonstrated a role in reducing biomarkers of these diseases. However, tirzepatide, a dual GLP-1 and GIP receptor agonist, considered more potent than semaglutide and analogues in resolving outcomes such as type 2 diabetes mellitus and weight loss, does not have its potential in the treatment of MASLD. and MASH is well understood, although there is evidence of reversal and control of these disorders in isolated clinical trials. Objective: To evaluate the improvement in clinical and laboratory parameters of MASLD or MASH in patients using tirzepatide. Method: Systematic Literature Review to be carried out in the Scielo, Pubmed, Scopus, EMBASE, Cochrane, Clinicals Trials, BVSalud/LILACS and Web of Science databases. Randomized controlled studies will be considered, with a publication period until May 2024. The descriptors will be considered, in English: "tirzepatide", "ly3298176", "MASLD", "MASH", "NAFLD" and "NASH", for In the search strategy, the descriptors "and" and "or" will be used. The investigation will be carried out directly by two researchers and the level of agreement between researchers will be assessed using the Kappa test (80%), SPSS (IBM®).